drugset
drugset / Trial / NCT04094077

Evaluating AGuIX® Nanoparticles in Combination With Stereotactic Radiation for Brain Metastases

NCT04094077 ↗

Phase 2 Terminated 1 enrolled Centre Leon Berard
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the clinical impact of AGuIX® nanoparticles in combination with Fractionated Stereotactic Radiation in oligo brain metastases.

Timeline

Start
2020-01-17
Primary completion
2021-02-24
Completion
2021-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject AGuIX Other / unclassified 100 mg/kg Intravenous

Indications

metastatic malignant neoplasm in the brain